BiotechTube
Home/Liquidia/Michael D. Jaffee
MD

Michael D. Jaffee

Chief Commercial Officer

Liquidia

Therapeutic Areas

Pulmonary HypertensionRare Cardiopulmonary Diseases

Liquidia Pipeline

DrugIndicationPhase
YUTREPIA™ (treprostinil) inhalation powderPulmonary Arterial Hypertension (PAH)Approved
LIQ861 (treprostinil) inhalation powderPulmonary Arterial Hypertension (PAH)Phase 3
L606 (liposomal treprostinil) injectionPulmonary Arterial Hypertension (PAH)Preclinical

Leadership Team at Liquidia

RA
Roger A. Jeffs, Ph.D.
President and Chief Executive Officer
MK
Michael Kaseta
Chief Financial Officer and Treasurer
TS
Tushar Shah, M.D.
Chief Medical Officer
TL
Timothy L. Turano
General Counsel and Corporate Secretary
SB
Steven B. Simonson, M.D.
Senior Vice President, Clinical Development
DL
David L. Tome
Senior Vice President, Operations and Supply Chain
PB
Paul B. Manning
Chairman of the Board
View full Liquidia profile